Jämför metoder
Granska de valda metoderna sida vid sida; rader som skiljer sig är markerade.
| Rome IV:s diagnostiska kriterier för irritabel tarm (IBS)× | Gastroparesis Cardinal Symptom Index× | |
|---|---|---|
| Ämnesområde | Gastroenterologi | Gastroenterologi |
| Familj | Process / pipeline | Process / pipeline |
| Ursprungsår≠ | 2016 | 2003 |
| Upphovsperson≠ | Rome Foundation (multinational expert consensus) | Revicki, D. A., Rentz, A. M., Dubois, D., et al. |
| Typ≠ | Diagnostic Criteria | Self-report |
| Ursprungskälla≠ | Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation. link ↗ | Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150. link ↗ |
| Alias≠ | Rome IV IBS, Rome Criteria | GCSI |
| Närliggande | 4 | 4 |
| Sammanfattning≠ | The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns. | The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response. |
| ScholarGateDatamängd ↗ |
|
|